Zevalin (IDEC Pharmaceuticals)
Zevalin (IDEC Pharmaceuticals) - General Information
Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Zevalin (IDEC Pharmaceuticals) is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Pharmacology of Zevalin (IDEC Pharmaceuticals)
Zevalin binds to the CD20 antigen, which is predominantly expressed on mature B cells and on > 90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
Zevalin (IDEC Pharmaceuticals) for patients
Zevalin (IDEC Pharmaceuticals) Interactions
No formal drug interaction studies have been performed with ZEVALIN. Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage. Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia. In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding.
Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.
Zevalin (IDEC Pharmaceuticals) Contraindications
The ZEVALIN therapeutic regimen is contraindicated in patients with known Type I hypersensitivity or anaphylactic reactions to murine proteins or to any component of this product, including Rituximab, yttrium chloride, and indium chloride.
Additional information about Zevalin (IDEC Pharmaceuticals)
Zevalin (IDEC Pharmaceuticals) Indication: For treatment of non-Hodgkin's lymphoma
Mechanism Of Action: Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. The chelate tiuxetan, which tightly binds radioactive In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Ibritumomab
Synonyms: Ig gamma-2A chain C region, membrane-bound form; radiolabeled murine anti-CD20
Drug Category: Antineoplastic Agents
Drug Type: Biotech; Approved
Other Brand Names containing Ibritumomab: Zevalin (IDEC Pharmaceuticals);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production
Half Life: 0.8 hours (mammalian reticulocytes, in vitro)
Dosage Forms of Zevalin (IDEC Pharmaceuticals): Not Available
Chemical IUPAC Name: Murine anti-CD20 antibody
Chemical Formula: C6382H9830N1672O1979S54
Ibritumomab on Wikipedia: https://en.wikipedia.org/wiki/Ibritumomab
Organisms Affected: Humans and other mammals